CIK 0001674416 · Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- operating
- EIN
- 473173478
- Phone
- 6173154600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,881,673
- in 7 filings, $1.5M under 10b5-1 plans
Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 60 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-06-11 | High Katherine A Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2019-06-11 | Bolzon Bradley J PhD Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2019-06-11 | Greene John Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2019-06-11 | CAGNONI PABLO J Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2019-06-11 | George Simeon Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2019-06-10 | Novak Rodger President | Sale | −50,000 | $45.00 | $2.3M | 898,007 |
| 2019-06-01 | Kulkarni Samarth Chief Executive Officer | Shares withheld for taxes | −741 | $35.57 | $26K | 165,801 |
| 2019-04-29 | Kulkarni Samarth Chief Executive Officer | Option exercise | +20,000 | $1.81 | $36K | 186,542 |
| 2019-04-29 | Kulkarni Samarth Chief Executive Officer | Sale | −20,000 | $42.03 | $841K | 166,542 |
| 2019-04-29 | Kulkarni Samarth Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | −20,000 | 223,058 | ||
| 2019-03-05 | Klein Lawrence Otto Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2019-03-05 | TOMSICEK MICHAEL JOHN Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2019-03-05 | KASINGER JAMES R. General Counsel and Secretary | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2019-03-05 | Ho Tony W See Remarks | Grant or award | +10,000 | $40.87 | $409K | 32,869 |
| 2019-03-05 | Ho Tony W See Remarks | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2019-03-05 | Kulkarni Samarth Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2019-03-04 | Novak Rodger President | Sale | −64,115 | $40.24 | $2.6M | 960,419 |
| 2019-03-04 | Novak Rodger President | Sale | −8,912 | $41.29 | $368K | 951,507 |
| 2019-03-04 | Novak Rodger President | Sale | −3,500 | $42.03 | $147K | 948,007 |
| 2019-03-01 | Novak Rodger President | Sale | −8,693 | $40.01 | $348K | 1,024,534 |
Page 47 of 62 · 1,221 trades